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Abstract 
Low grade inflammation, endothelial dysfunction and platelet hyper-reactivity to agonists are 
associated with an increased risk of cardiovascular events. In vitro and animal studies infer an 
inverse mechanistic relationship between platelet activation and the production of 
endothelium-derived nitric oxide and prostacyclin. This concept is supported by evidence of 
an inverse relationship between endothelial function and platelet activation in high-risk 
cardiac patients. The aim of the present study was to investigate what relationship, if any, 
exists between platelet and endothelial function in healthy, middle-aged and elderly adults. In 
fifty one participants (18 male, 33 post-menopausal female), endothelial function was 
assessed by flow mediated dilation (FMD). Platelet function was assessed by flow cytometric 
determination of glycoprotein IIb/IIIa activation (measured by PAC-1 binding), granule 
exocytosis (measured by surface P-selectin expression) and monocyte-platelet aggregates 
(MPAs), with and without stimulation by canonical platelet agonists adenosine diphosphate 
(ADP), arachidonic acid (AA) and collagen. Correlation analysis indicated there was no 
significant (all P=>0.05) relationship between FMD and any marker of in vivo platelet 
activation (MPAs R= 0.193, PAC-1 R= −0.113, anti-CD62P R= −0.078) or inducible platelet 
activation by ADP (MPA R= −0.128, anti-CD62P R= −0.237), AA (MPA R= −0.122, PAC-1 
R= −0.045, anti-CD62P R= −0.142) or collagen (MPA R= 0.136, PAC-1 R= 0.174, anti-
CD62P R= −0.077). Our findings contrast with two previous studies performed in high risk 
cardiac patients, which reported inverse relationships between platelet activation and 
endothelial function, suggesting that some compensatory redundancy may exist in the 
relationship between platelet and endothelial function in pre-clinical populations. 
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New & Noteworthy  
In this study which included healthy middle-aged and elderly adults, we compared measures 
of in vivo endothelial function and platelet activation, risk factors for cardiovascular disease 
that are inversely associated in high-risk cardiac patients. Some compensatory redundancy 
may exist in these variables in pre-clinical populations. 
Key Words: endothelial function, platelet function, cardiovascular disease 
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Introduction 
Thrombosis is an integral component of acute coronary syndromes such as acute myocardial 
infarction (MI) and ischemic stroke (12, 23). Moreover, the role of platelets in the early, 
dormant stages of atherosclerosis and cardiovascular disease (CVD) has recently been 
recognized (26, 40). Low grade inflammation, endothelial dysfunction and platelet hyper-
reactivity to agonists are all independently associated with an increased risk of cardiovascular 
events (15, 24). An intact and healthy endothelium regulates and inhibits platelet activation 
(9) and endothelial dysfunction may play a direct role in activating platelets (8). Platelet 
activation results in the formation of monocyte-platelet aggregates (MPAs) (27), and stepwise 
increases in MPAs and activated platelets have been observed with cardiovascular disease 
progression (28). The interaction between activated platelets and monocytes can initiate the 
release of pro-inflammatory and adhesive molecules that are atherogenic (13, 30, 32, 50), 
driving a pro-atherogenic monocytic phenotype (4) and facilitating the infiltration of 
monocytes to the sub-intima space (30, 47). 
 
A number of in vitro experiments suggest that nitric oxide (NO) and prostacyclin (PGI2), 
produced by endothelial cells, directly inhibit platelet aggregation (2, 3, 29). However, the 
functional relationship between platelet activation and endothelial function in vivo is less 
clear (31, 38). Whilst inhibition of NO production in healthy young adults can increase 
platelet activation (42) and decrease clotting time (44), this is not a universal finding (1) and 
these studies assessed the acute impact of pharmacological blockade. An inverse relationship 
between endothelium-dependent coronary vasomotor function and MPAs measured in arterial 
samples has been documented in high risk patients undergoing cardiac angiography and 
angioplasty (11, 17). There is also evidence to suggest that pharmacological blockade of the 
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platelet fibrinogen receptor (glycoprotein IIb/IIIa receptor) (18) and administration of the 
anti-platelet medications clopidogrel (16, 35, 37, 46) and aspirin (20, 48) can acutely improve 
endothelial function in patients with CAD.  However, these short term effects were abolished 
when administration was maintained for longer periods of time (36). One previous study (22) 
has investigated the relationship between in vivo endothelial function, assessed using brachial 
artery flow mediated dilation (FMD) and platelet function assessed via flow cytometry (14). 
This study was conducted in adolescents, with or without a positive family history of CAD, 
and no relationship was found between FMD and platelet activation (MPAs, PAC-1 or 
CD62P binding).  
 
Increasing age and physical inactivity are risk factors for cardiovascular disease (43), but no 
previous study, to our knowledge, has investigated relationships between endothelial function 
and platelet activation in asymptomatic healthy older adults, or whether any such relationship 
extends to agonist-induced platelet activation. Therefore, our aim was to test the relationship, 
if any, between platelet and endothelial function in apparently healthy, physically inactive, 
middle-aged and elderly humans. We hypothesized that FMD would be inversely associated 
with the presence of MPAs and activated platelets; and inversely associated with agonist-
induced platelet activation. 
 
Materials and Methods 
The study was approved by the University of Western Australia Human Research Ethics 
Committee, procedures were in accord with the Declaration of Helsinki and participants 
provided written informed consent. 
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Male and post-menopausal female participants were recruited from the general population in 
Perth, Western Australia using multiple recruitment strategies including advertisements in 
local newspapers, radio stations and posters. Apparently healthy individuals aged 45yrs and 
over were encouraged to contact the research team, resulting in initial phone screening 
procedures which included questionnaires to determine suitability to attend a formal 
screening visit. Initial exclusion criteria included serious illness such as cancer, diagnosed 
cognitive impairment or dementia, current or past history of ischemic heart disease, angina, 
stroke, persistent arrhythmias, diabetes mellitus, airway disease, epilepsy, severe mental 
illness, engaging in more than 1 hour of physical activity per week, current or recent smokers 
(within 12 months), pre- or peri-menopausal females and alcohol consumption >28 standard 
drinks/wk. 
 
Individuals satisfying the initial criteria were invited to attend a screening session during 
which a number of measures were collected including: height, body mass, resting 
electrocardiogram (ECG) and fasting blood tests (glucose, lipid profile, full blood count, urea 
and electrolytes). Participants exhibiting abnormal cardiac rhythms, blood test results 
suggestive of chronic kidney disease, diabetes, or total cholesterol >7mmol/L were excluded. 
Included participants were then invited to perform an exercise stress test with ECG 
monitoring and those with evidence of exertion-induced myocardial ischemia were excluded 
from further participation. In subsequent visits, participants underwent a 20 minute resting 
blood pressure (BP) assessment and a dual energy x-ray absorptiometry (DEXA) scan. For 
the resting BP assessment, participants arrived at the laboratory in the morning following an 
overnight fast and lay in a supine position in a temperature controlled dark room. BP was 
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measured every 2 minutes by an automated device (Dinamap V100, GE Healthcare, USA). 
Individuals with an average systolic BP >160mmHg or diastolic BP >100mmHg were 
excluded. 
 
For flow mediated dilation (FMD) and platelet function tests, participants arrived at the 
laboratory in the morning between 7:00-9:30am, following an overnight fast, having 
abstained from the consumption of caffeine and alcohol for 12 and 24 hours respectively and 
not taken part in physical exercise for 24 hours. Adherence to the protocol was confirmed by 
questionnaire on arrival. Prior to attending the laboratory for data collection, participants 
were instructed to be clear of symptoms for 7 days if they had recently suffered with acute 
conditions including respiratory tract infection, cold and flu. Participants taking prescription 
medications were instructed to maintain their usual routine of administration. However, the 
use of non-prescribed medications such as anti-inflammatory, anti-histamine, antibiotic, 
aspirin, cold and flu medications were ceased for at least 7 days prior to blood collection. 
Participants lay supine in a cool temperature controlled room for 15 minutes, after which a 
blood sample was collected from the dominant arm for the assessment of platelet function. 
Subsequent FMD tests were performed on the non-dominant arm.  
 
Blood Collection 
A venous blood sample was collected into a 4mL 3.2% sodium citrate tube (Vacuette by 
Greiner bio-one) and processed according to published standards (27), as pre-analytical 
variables during blood collection, storage and handling are an important factor in platelet 
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function testing. Within 10 minutes of collection, blood was processed to assess circulating 
levels of MPAs and activated platelets and their sensitivity to platelet agonists. 
 
Monocyte-platelet aggregates 
Each MPA reaction tube included two antibodies: CD14 (monocyte identifier) conjugated to 
the fluorophore Brilliant Violet (BV) 421 (Clone M5E2, BioLegend, San Diego CA) and 
CD42b (platelet identifier) conjugated to Allophycocyanin (APC) (Clone HIP1, BioLegend) 
or IgG isotype control (BioLegend). Six MPA reaction tubes (Protein LoBind Eppendorf, 
Germany) were included: isotype control, no agonist, positive control (250µM thrombin 
receptor activating peptide-6 (SFLLRN, Sigma-Aldrich, MO)), and threshold (low) 
concentrations of the following three agonists: adenosine diphosphate (ADP) 1.5µM 
(Chrono-Log Corp., PA), arachidonic acid (AA) 10µg/mL (Sodium arachidonate, Bio/Data 
Corp., PA) and collagen 1.5µg/mL (Chrono-Log Corp., PA). Absence of spectral overlap was 
confirmed by single-colour comp bead controls (BD Biosciences). Samples were fixed and 
red cells lysed with 800µL of BD FACSLyse solution (BD Biosciences) following exactly 15 
minutes of incubation. Samples were then stored in the dark at 4°C and analyzed by flow 
cytometry (BD FACSCantoTM II, BD Biosciences) at a low flow rate for 10 minutes per tube, 
to avoid coincident events (19). 
 
Platelet surface receptors 
Whole blood was diluted 1:5 with HEPES saline buffer and incubated with a cocktail of the 
following fluorescent conjugated antibodies at saturating concentrations: PAC-1 fluorescein 
(FITC), CD62P phycoerythrin (PE), CD42b PE-Cy5, or IgG1Κ PE isotype control (all BD 
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Pharmingen) for exactly 15 minutes. Six reaction tubes were used that were identical in 
function and agonist concentrations as those used for MPAs. However, ADP at the 
concentration used (1.5µM) caused maximal PAC-1 binding in all participants, so was not 
included in statistical analysis. Following incubation, samples were fixed with 800µL of 
stabilizing fixative (BD Biosciences) and were then stored at 4°C until analysis by flow 
cytometry (BD FACSCanto II) within 24 hours. Samples were run at a low flow rate until 
10,000 platelet positive events were counted. To account for spectral overlap between the 
three fluorophores, single stained compensation beads were used (BD Biosciences). For both 
MPAs and platelet surface receptor binding, samples were incubated at room temperature 
with the exception of tubes containing AA and collagen, which were incubated at 37°C using 
a dry block heater (Ratek DBH20D, Victoria, Australia).  
 
Flow mediated dilation (FMD) 
The vascular assessments were conducted in a quiet, temperature-controlled room in 
accordance to recent guidelines (45). To examine brachial artery FMD, the non-dominant arm 
was extended and positioned at an angle of ~80° from the torso. A rapid inflation and 
deflation pneumatic cuff (D.E. Hokanson, Bellevue, WA, USA) was positioned on the 
forearm, immediately distal to the olecranon process to provide a forearm ischemia stimulus. 
Using this approach, the brachial artery dilation represents a largely NO-mediated, 
endothelium-dependent response (14). A 10-MHz multi-frequency linear array probe, 
attached to a high-resolution ultrasound machine (T3200; Terason, Burlington, MA, USA) 
was used to image the brachial artery in the distal 1/3rd of the upper arm. When an optimal 
image was obtained, the probe was held stable and the ultrasound parameters were set to 
optimise the longitudinal, B-mode images of lumen–arterial wall interface. Continuous 
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Doppler velocity assessments were also obtained using the ultrasound, and were collected 
using the lowest possible insonation angle (always <60°). Following a 1-min baseline 
recording of brachial artery diameter and velocity (Camtasia Studio 8, TechSmith, Okemos, 
MI), which were used to examine baseline blood flow patterns, the forearm cuffs were 
inflated (220mmHg) for 5 min. Diameter and flow recordings resumed 30s prior to cuff 
deflation and continued for 3 min thereafter. Post-test analysis of brachial artery diameter was 
performed using custom-designed edge-detection and wall-tracking software, which is largely 
independent of investigator bias (49). Brachial artery FMD is presented as relative (%) rise 
from the preceding baseline diameter. We have shown that the reproducibility of diameter 
measurements using this semi-automated software is significantly better than manual 
methods, reduces observer error significantly, and possesses an intra-observer CV of 6.7%. 
 
Statistical Methods 
To test whether there was a relationship between FMD and platelet function, a Pearson 
product-moment correlation test was carried out for data that were normally distributed. For 
data that were not normally distributed, a Spearman’s Rank test was conducted. 
Subsequently, to determine if potential confounding factors including: age, gender, resting 
heart rate and blood pressure, body fat percentage, fasting blood glucose and lipids, and 
medication use impacted upon the results, partial correlations were conducted to account for 
these co-variates. Participants were then divided into 2 groups based on gender, and 
correlation analysis between FMD and platelet function was conducted for males and females 
separately to determine if results were gender specific. To test whether any differences 
existed between male and female participants for FMD or any of the platelet function 
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variables measured, independent sample T-tests and Mann-Whitney U tests were conducted 
for data meeting and failing normality assumptions respectively.    
 
Results 
Fifty one participants (18 male, 33 female) were included in the study and underwent platelet 
function and FMD tests. The general characteristics of participants included in the study are 
presented in Table 1. Two participants failed to receive a DEXA scan, so for data derived 
using this outcome measure n=49. Descriptive statistics for vascular and platelet function 
outcome measures can be seen in Table 2. An error in the processing of platelet PAC-1 and 
CD62P with no agonist occurred for 1 participant and for PAC-1 and CD62P with AA 
incubation for 1 other participant. Therefore, for the direct comparison of all MPA data vs 
FMD n=51, but for PAC-1 and CD62P NA and AA n=50.  
 
Relationships between FMD and platelet activation  
No significant relationship was found between FMD% and circulating levels of activated 
platelets, whether measured by MPAs (Figure 1), PAC-1 (Figure 2) or anti-CD62P (Figure 3) 
binding (all P >0.05). No relationship was observed between FMD% and platelet reactivity to 
the agonists ADP (MPA & CD62P only), AA or collagen for MPAs, PAC-1 or anti-CD62P 
binding (all P >0.05). All correlation results can be found in Table 2.  
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Impact of potential confounding variables 
Inspection of scatter plots suggested that no linear relationship existed between any of the 
potential confounding variables (age, gender, resting heart rate, blood pressure, % body fat, 
fasting glucose and lipids (triglycerides, cholesterol, LDL and HDL) and medication use) and 
FMD% or any of the platelet function parameters. Consequently, the results of partial 
correlation testing indicated that no significant relationship (all P >0.05) existed between 
FMD% and any of the measures of platelet function we studied when these potentially 
confounding variables were included as co-factors (see Table 3).   
 
Potential gender differences 
Independent correlation analyses conducted for male and female participants individually 
revealed there were no significant relationships between FMD and any of the platelet 
function variables we measured for either gender (all P = >0.05). No significant differences 
were found between male and female participants for FMD (P = 0.767), MPA NA (P = 
0.554), MPA ADP (P = 0.577), MPA AA (P = 0.419), MPA collagen (P = 0.608), PAC-1 
NA (P = 0.928), PAC-1 AA (P = 0.524), PAC-1 collagen (P = 0.150), CD62P NA (P = 
0.146), CD62P ADP (P = 0.585), CD62P AA (P = 0.565), CD62P collagen (P = 0.086). 
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Discussion 
Endothelial dysfunction and increased platelet activation are both associated with 
cardiovascular disease progression (9, 10) and, based on in vitro and animal studies, it is 
often inferred that a direct and inverse relationship exists between the function of the 
endothelium and platelet activation (2, 3, 41, 42). The aim of the present study was to 
investigate the relationship between endothelial function and platelet activation in a pre-
clinical low-risk population of older participants with low physical activity levels. In this 
study, we did not find any relationship between flow mediated dilation, an indicator of 
endogenous nitric oxide and prostacyclin bioavailability (14), and platelet function assessed 
by flow cytometry. 
 
Our findings were unexpected, as the extant literature suggests there is an inverse relationship 
between platelet and endothelial function (11, 16-18, 20, 35, 37, 41, 42, 46). In contrast to our 
study, two previous investigations have reported an inverse relationship between vascular 
function and MPAs in high-risk cardiac patients (11, 17). These studies utilized highly 
invasive vascular tests (coronary vasomotor function) and measured platelet activation in 
arterial blood samples. We tested endothelial function in the brachial artery following 
established guidelines, a common and reproducible approach (34, 45). Platelet function was 
interrogated in venous blood samples with multiple outcomes (ie MPAs, PAC-1 and anti-
CD62P binding), with and without canonical platelet agonists, using sophisticated and 
established flow cytometry techniques (27) which have been associated with cardiovascular 
outcome. It is possible that differences in participant characteristics and/or methodological 
approaches between our study and these previous reports are responsible for the divergent 
findings. In critically ill patients with sepsis, MPAs in arterial blood were ~60% greater 
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compared to MPAs in venous blood (39), but to our knowledge no investigation has 
determined if sampling technique confers physiological or pathological relevance, or if such a 
difference exists in healthy individuals. 
 
The majority of studies that have reported an inverse relationship between platelets and 
endothelial function have involved pharmacological modulation of these variables using 
acute experiments in humans (16, 18, 20, 35, 37, 42, 46). In one such study, platelet 
activation was increased by blockade of endothelium-derived nitric oxide using a bolus dose 
of NG-monomethyl-L-arginine (42), whereas lower doses of blockade did not induce such 
changes (1). Likewise, increases in FMD have been observed following a single loading dose 
of clopidogrel and vasodilation responses post-administration were dose-dependent (46). 
Research in which a significant association was observed between platelet and endothelial 
function has involved participants with established coronary disease undergoing cardiac 
angiography and angioplasty. Such individuals exhibit large changes in platelet activation and 
endothelial function (12, 28) and possess an inflammatory state (25) that may partly explain 
the inverse relationship observed. In contrast, there is some evidence to suggest up-regulation 
of NO-synthase mediated endothelial function occurs in the presence of CVD risk factors (7, 
33) and it is possible that, in sub-clinical and apparently healthy populations with risk factors 
for CVD, some compensatory redundancy exists in the interaction between the endothelium 
and platelets. This could account for the lack of an inverse relationship between these two 
variables in our study. Furthermore, there is some evidence to suggest that compensatory 
mechanisms that prevent spontaneous thrombosis and preserve hemostatic function occur in 
mice incapable of producing NO (21). Indeed, the percentage of circulating MPAs in our 
cohort (4.1 ± 1.4 %) were far lower than that reported in samples taken from high risk cardiac 
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(~20-38%) (11, 17) and stable CAD (~12%) patients (28), even after considering the potential 
differences in MPAs between arterial and venous blood (39). 
 
Our findings do not necessarily conflict with the established role of platelet and endothelial 
function in atherosclerosis, highlighted in recent reviews (6, 9, 30). However, because 
atherosclerosis evolves slowly over many decades in humans, it is possible that the 
relationship between endothelial and platelet function in healthy individuals is less apparent 
and/or detectable, even with the sensitive technical approaches used in the present study. In 
contrast, transgenic mouse models provide a relatively accelerated and exaggerated insight 
into disease pathogenesis (5). Diabetic mice with lower NO bioavailability exhibit higher 
basal levels of activated platelets compared to control mice (41), whereas mice with induced 
diabetes but preserved NO-bioavailability due to over-expression of tetrahydrobiopterin 
possess normal levels of activated platelets. These findings suggest that in accelerated 
pathological models and/or in certain advanced disease states (eg CAD, diabetes mellitus), 
increased platelet activation and reduced endothelial NO may be mechanistically relevant. 
Although we deliberately recruited healthy middle-aged and elderly individuals in this study, 
future research should include a wide range of participants, across the lifespan. A potential 
limitation to the current study is the limited sample size, but previous studies which have 
reported a significant inverse relationship between FMD and platelet activation have included 
30 (11) and 19 (17) patients, so this is unlikely to be responsible for the lack of relationship in 
the current study. 
 
There are several limitations to our study. We constrained recruitment to >45yrs and all 
women were post-menopausal. Our average FMD results indicate a relatively lower response 
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than studies involving younger cohorts, in keeping with the established impact of age on 
vascular function. Nonetheless, we cannot generalize our findings to younger or much older 
age groups. Similarly, our study excluded participants with established cardiovascular 
diseases and, as mentioned above, correlations between platelet and endothelial function may 
be more apparent in those with overt disease. Finally, whilst some of our participants were 
taking medications, sub-group analysis revealed no impact of drugs on the magnitude or 
pattern of correlation in our study. Notably, all participants taking medications specifically 
known to impact upon platelet function were excluded from our study. 
 
In summary, we did not observe any relationship between endothelial function and platelet 
activation in the healthy, middle-aged and elderly participants we recruited in this study. As 
our findings contrast with some previous studies conducted in high risk cardiac patients, our 
data suggest that some compensatory redundancy may exist in the relationship between 
platelet and endothelial function in pre-clinical populations.  
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Figure Captions   
Figure 1 
Individual responses for MPAs no agonist (NA) vs flow mediated dilation (FMD%) and 
results of correlation analysis. N=51 
Figure 2 
Individual responses for platelet PAC-1 binding no agonist (NA) vs flow mediated dilation 
(FMD%) and results of correlation analysis. N=50 
Figure 3  
Individual responses for platelet anti-CD62P binding no agonist (NA) vs flow mediated 
dilation (FMD%) and results of correlation analysis. N=50 
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Table 1 General characteristics, anthropometric and dual-energy x-ray absorptiometry 
(DEXA) and biochemistry variables  
 
Age (yrs) 
Anthropometric data 
Height (cm) 
Body mass (kg) 
Body mass index (kg/m2) 
Total body fat % (DEXA) n=49 
 
Resting HR & blood pressure 
Heart rate (bpm) 
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Mean arterial pressure (mmHg) 
 
Fasting Biochemistry (mmol/L)  
Cholesterol  
Triglyceride  
LDL-C  
HDL-C  
Glucose  
 
Prescription Medication  
Any medication  
Blood Pressure medication total 
    Ca channel block 
    Beta Blocker 
    Angiotensin II receptor antagonist 
Statins  
Anti-depressant 
All participants 
 60.6 ± 7.4 
 
166.5 ± 8.0 
  76.9 ± 15.8 
  27.6 ± 4.5 
  39.5 ± 7.3 
 
     
    62 ± 7 
  123 ± 14 
    72 ± 9 
    92 ± 10 
   
 
  5.6 ± 0.9 
   1.2 ± 0.7 
   3.6 ± 0.8 
   1.4 ± 0.3 
   5.1 ± 0.4 
  
N (dual meds) 
12 (3) 
6   (3) 
2 
1 
3 
6  (3) 
3 
      Male 
  57.1 ± 6.3 
 
173.8 ± 4.8 
  89.8 ± 11.1 
  29.8 ± 3.7 
  34.1 ± 1.2 
 
 
   
 127 ± 12 
     79 ± 9 
     98 ± 9 
 
    
 5.5 ± 1.1 
    1.6 ± 0.6 
    3.6 ± 0.9 
    1.1 ± 0.2 
    5.3 ± 0.1 
 
 
         3 
         2 
 
 
 
          1 
     Female 
  62.3 ± 7.6 
 
162.2 ± 6.0 
  70.0 ± 13.0 
  26.6 ± 4.6 
  42.4 ± 6.8 
 
 
   
 121 ± 14 
     69 ± 6 
     89 ± 8 
 
 
    5.6 ± 0.7 
    1.1 ± 0.7 
    3.6 ± 0.7 
    1.5 ± 0.3 
    5.0 ± 0.1 
 
 
          9 
          4 (3) 
 
 
 
          5 (3) 
          3 
Dual energy X-ray absorptiometry DEXA, Heart rate HR, Blood pressure BP, Low-density 
lipoprotein cholesterol LDL-C, High-density lipoprotein cholesterol HDL-C. Values are 
Mean ± SD with exception of Prescription Medication presented as total N. N=51 unless 
stated otherwise. 
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Table 2 Descriptive statistics of FMD and platelet function tests, and 
results of correlation tests between FMD% and platelet function  
 
FMD% 
BD (mm) 
PD (mm) 
Platelet Variable % 
Mean ± SD 
  4.6 ± 2.5 
  3.6 ± 0.7 
  3.8 ± 0.7 
 
 
   
 
    R=            P= 
MPA NA 
MPA ADP1.5µM 
MPA AA10µg/ml 
MPA Coll 1.5µg/ml 
 
PAC-1 NA (n=50) 
PAC-1 AA10µg/ml (n=50) 
PAC-1  Coll 1.5µg/ml 
 
CD62P NA (n=50) 
CD62P ADP1.5µM 
CD62P AA10µg/ml (n=50) 
CD62P Coll 1.5µg/ml 
  4.1 ± 1.4  
47.8 ± 16.8 
20.8 ± 25.3 
  5.3 ± 5.5  
 
  4.7 ± 5.4 
23.3 ± 17.3 
22.3 ± 20.6 
 
  1.8 ± 1.4  
58.7 ± 19.1 
13.5 ± 11.8 
  8.8 ± 10.1 
  0.193 
−0.128 
−0.122 
  0.136 
 
−0.113 
−0.045 
  0.174 
 
−0.078 
−0.237 
−0.142 
−0.077 
0.175 
0.369 
0.396 
0.340 
 
0.433 
0.755 
0.223 
 
0.591 
0.094 
0.324 
0.591 
 FMD Flow mediated dilation, BD baseline diameter, PD peak diameter,  
Monocyte-platelet aggregate MPA, No agonist NA, Adenosine 
diphosphate ADP, Arachidonic acid AA, Collagen Coll. N=51 unless 
stated otherwise. 
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 Table 3 Results of partial correlation tests between 
FMD% and platelet function accounting for the potential 
influence of co-variates   
Platelet Variable    R=              P= 
MPA NA 
MPA ADP1.5µM 
MPA AA10µg/ml 
MPA Coll 1.5µg/ml 
 
PAC-1 NA (n=50) 
PAC-1 AA10µg/ml (n=50) 
PAC-1  Coll 1.5µg/ml 
 
CD62P NA (n=50) 
CD62P ADP1.5µM 
CD62P AA10µg/ml (n=50) 
CD62P Coll 1.5µg/ml 
  0.119 
−0.071 
  0.015 
−0.091 
 
−0.075 
−0.155 
−0.005 
 
  0.066 
−0.246 
−0.091 
  0.034 
0.484 
0.675 
0.928 
0.592 
 
0.664 
0.368 
0.975 
 
0.704 
0.143 
0.598 
0.844 
 FMD Flow mediated dilation, Monocyte-platelet 
aggregate MPA, No agonist NA, Adenosine diphosphate 
ADP, Arachidonic acid AA, Collagen Coll. Co-variates 
include: age, gender, body fat percentage, resting heart 
rate and blood pressure, fasting glucose and lipids and 
medication use. N=51 unless stated otherwise. 
 
 
